Acute Hypomagnesaemia Protocol The Master Electrolyte · Assess · Replace · v1.0
Workflow: Enter the patient's magnesium level, concurrent potassium and calcium status, ECG findings, symptoms, and clinical context. The tool generates a stepwise replacement protocol and identifies downstream electrolyte consequences.
1. Biochemical Status
2. Symptoms & Access
3. Clinical Modifiers & Causes
The Master Electrolyte: Why Magnesium Controls Everything

Magnesium is a cofactor for over 300 enzymatic reactions, including the Na+/K+-ATPase pump (critical for K homeostasis), adenylate cyclase (critical for PTH signalling and Ca homeostasis), and ATP metabolism. Hypomagnesaemia causes: (1) Refractory hypokalaemia (ROMK channel activation → renal K wasting), (2) Refractory hypocalcaemia (impaired PTH secretion + skeletal PTH resistance), (3) Cardiac arrhythmias (prolonged QT, Torsades de Pointes). Fixing magnesium first is often the key to fixing everything else.

IV MgSO4: Rate Limits & Safety
SeverityDoseRateNotes
Mild (1.5-1.7)1-2g MgSO4Over 1 to 2 hoursOral preferred if tolerated
Moderate (1.0-1.4)2-4g MgSO4Over 4 to 6 hoursIV preferred. Follow with oral maintenance.
Severe (< 1.0)4-6g MgSO4 loadingFirst 2g over 5 to 15 min, then remainder over 6 to 12 hMonitor for Mg toxicity: loss of DTRs, resp depression
Cardiac arrest / TdP2g MgSO4 IV pushOver 2 to 5 minutesUndiluted push is acceptable in arrest settings
⚠ MgSO4 Toxicity Signs (in order of appearance):
(1) Loss of deep tendon reflexes (DTRs) - CHECK BEFORE EACH DOSE. (2) Respiratory depression. (3) Hypotension. (4) Cardiac arrest (bradycardia → asystole). Antidote: IV Calcium Gluconate 10 mL (10%) over 3 minutes.
The PPI Problem

Chronic PPI use (Omeprazole, Pantoprazole, Rabeprazole - ubiquitous in Indian practice) reduces intestinal magnesium absorption via inhibition of TRPM6/7 channels. This effect is not dose-dependent and can occur with any PPI. Onset: typically after months to years of use. It is NOT corrected by IV or oral Mg replacement while the PPI continues - the absorptive defect persists. Management: switch to H2-blocker (Ranitidine/Famotidine) if possible. If PPI is essential, add high-dose oral Mg supplementation and monitor levels regularly.

Oral Magnesium: Indian Formulations
PreparationElemental MgBioavailabilityGI ToleranceIndian Brands
Magnesium Oxide60% by weightLow (4%)Poor (diarrhoea)Mag-SR, Magox
Magnesium Hydroxide42%LowLaxative effectMilk of Magnesia
Magnesium Citrate16%ModerateGoodLimited availability
Magnesium Glycinate14%HighBest toleratedMagTech, Now Foods
Magnesium L-Threonate8%High (CNS penetration)GoodSpecialty import

Practical note: The most commonly available oral Mg in Indian government hospitals is Magnesium Oxide (Mag-SR 400 mg = ~240 mg elemental Mg). Despite poor bioavailability, it is effective at higher doses. The main limitation is GI side effects (diarrhoea), which ironically can worsen Mg depletion.

Magnesium and Torsades de Pointes

IV MgSO4 2g is the first-line treatment for Torsades de Pointes (TdP), regardless of the serum magnesium level. Magnesium works by suppressing early afterdepolarisations (EADs) that trigger TdP. This is one of the few situations where Mg is given emergently even if the serum level is normal. Administer 2g IV MgSO4 over 2 to 5 minutes in active TdP. Follow with an infusion of 1 to 2g/hour for 4 to 6 hours.

Abbreviations: Mg (Magnesium) · MgSO4 (Magnesium Sulphate) · K+ (Potassium) · Ca (Calcium) · DTR (Deep Tendon Reflex) · TdP (Torsades de Pointes) · PPI (Proton Pump Inhibitor) · TRPM (Transient Receptor Potential Melastatin) · ROMK (Renal Outer Medullary Potassium channel)
Algorithm References & Evidence Base
  1. Ayuk J, Gittoes NJL. How should hypomagnesaemia be investigated and treated? Clin Endocrinol. 2011;75(6):743-746.
  2. Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in Hospitalized Patients: Prevalence and Prognostic Importance. Mayo Clin Proc. 2015;90(9):1202-1213.
  3. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405-413.
  4. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649-2652.
  5. Kolte D, Vijayaraghavan K, Khera S, et al. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014;22(4):182-192.
How to Cite This Tool

AMA Style:
Umakanth S. Acute Hypomagnesaemia Protocol. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Acute Hypomagnesaemia Protocol [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Category Therapeutic Pathways & Algorithms
Specialties Internal Medicine, Nephrology, Critical Care
Status New Pathway